Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Full-year 2025 earnings results disclosed via press release (Exhibit 99.1).
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 earnings results disclosed via press release (Exhibit 99.1)
- Reporting period: fiscal year ended December 31, 2025
- Full financial details: revenue, net income, guidance, contained in attached Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.